Shares of Aridis Pharmaceuticals Inc (NASDAQ:ARDS) have been given a consensus recommendation of “Buy” by the seven brokerages that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $30.60.
Several equities research analysts have commented on the stock. ValuEngine raised shares of Aridis Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Zacks Investment Research cut shares of Aridis Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, August 15th. Northland Securities reissued a “buy” rating and set a $40.00 price target on shares of Aridis Pharmaceuticals in a research report on Tuesday, August 13th. Finally, Maxim Group reissued a “buy” rating and set a $25.00 price target on shares of Aridis Pharmaceuticals in a research report on Thursday, August 15th.
NASDAQ:ARDS traded down $0.32 on Thursday, hitting $7.71. 125 shares of the company’s stock were exchanged, compared to its average volume of 3,850. The firm has a 50-day moving average price of $9.16 and a 200-day moving average price of $9.42. Aridis Pharmaceuticals has a 52 week low of $6.91 and a 52 week high of $13.85. The company has a market cap of $68.71 million and a P/E ratio of -1.10.
About Aridis Pharmaceuticals
Aridis Pharmaceuticals Inc, a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S.
Further Reading: What are the economic characteristics of a bear market?
Receive News & Ratings for Aridis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aridis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.